The main aim of the GO-GRASS project is to create new business opportunities in rural areas based on grassland and green fodder that will be demonstrated in four EU regions at small scale, ensuring its replicability all through the rural communities of the EU. Inside a circular system, GO-GRASS will provide a range of circular and sustainable business models with high replication potential, to be available to entrepreneurs and local authorities. The project will also demonstrate innovative cost-effective technologies, processes and tools applicable within the diverse DEMO scenarios (deploying demonstrators in different regions in EUas representative places to cover different rural contexts) considering social, economic and environmental circumstances in rural areas with the aim of achieving a large-scale replication, especially in remote areas with unexploited resources. Furthermore, the GO-GRASS project will help EU reducing imports from nutrients like P or even proteins, as well as the dependence from fossil fuels. Thanks to the GO-GRASS project, the Bioeconomy will be consolidated, harnessing regional assets, diversifying and revitalizing the economy and providing quality jobs and opportunities in rural areas. In addition, the production and use of bio-based products replacing existing fossil-based alternatives, such as fertilisers or plastic packaging, can make a considerable impact on the Agro-food systems greenhouse gases emissions at EU level. For achieving this aim, GO-GRASS consortium consists of a multidisciplinary team of 22 partners from 8 European countries (Germany, Spain, Denmark, Sweden, The Netherlands, Belgium, Romania and Hungary). The consortium is built around the four regional demos located in Germany , Denmark , The Netherlands and Sweden that integrate the multi-actor approach concept, with the expertise of multiple appropriate partners (farmers, research centres, technological companies),3 follower partners and other with transversal role

Emerging technologies as Offshore Wind Energy, demand new advanced solutions for reducing Operation & Maintenance (O&M) costs, as well as for performing the reliability and extended life-time of wind turbines (WT) and farms (WF). In this sense, ROMEO is a 5 years project whose main objective is to develop and demonstrate an O&M information management and analytics platform capable of improving the decision making processes of offshore WF operators allowing the transition from calendar base maintenance to condition-based maintenance strategies reducing significantly O&M costs. Thus, a flexible and interoperable IoT platform will provide an advanced analytics ecosystem to better understand the real time behaviour of the main components of the WTs under operation conditions; maximizing their life-time and reducing the need for maintenance, thus minimizing the OPEX which drastically impact on LCoE of offshore Wind Energy. The project has been structured in three phases: 1st phase “specifications” will pave th

Extracellular vesicle (EVs) nanoparticles are the universal agents of intercellular and inter-organismal communication “made by cells for cells” to shuttle lipids, proteins and nucleic acids, EVs mediate physiological processes and help to spread various diseases, including cancer and infections. Their innate navigation performances take origin in the unique structure and composition of their membrane (which is to date inaccessible to synthetic mimics). The main goal of the BOW project is to explore and consolidate the technology able to impart biological surface precision, circulation and targeting abilities of EVs to superparamagnetic nanodevices (Magnetic Bead Devices, MBDs) by “dressing” them with a single- or multi-layer “wetsuit” of EV membrane “fabric”. This will proof and set a general, viable paradigm to recapitulate key biomimetic functions – including camouflage to the immune system and organ site/tumor targeting – to any synthetic nanodevice, while being disruptive as a first example of biogenic nanotechnology. If successful, such a non-incremental technology will promote the progress of implantable nanodevices and nanomaterials towards sustainable production and clinical translation, contributing to strengthen and keep in the lead position European biotechnology and impacting life quality for people. Major objectives include: (i) production high-grade EVs with biomimetic and organotropic functions, (ii) synthesis and functionalization of MBDs, (iii) engineering a microfluidic device for streamlined fabrication of EV membrane coated MBDs (evMBDs) (iv) evaluation of evMBD biological performances and nanotoxiciy in-vitro, ex-vivo and in-vivo. BOW will be made possible thanks to a balanced ecology-biology-biophysics-chemistry-engineering matrix, of well-established and internationally recognized academics (7), high biotech SMEs (3), plus 1 innovation consulting, contributing to strengthen European pool of expertise and biotechnology innovation eco-system.

Nowadays, the European construction market has to tackle the refurbishment of existing building stock. NZEB renovation methodologies are required as a key enabler through energy-efficient buildings. REZBUILD will address this challenge by opening the construction sector through the integration of innovative technologies such as leaves in a tree in order to pave the way towards an annual renovation rate of 2,5% instead of current rates lower than 1%. The aim is to develop one refurbishment ecosystem based on the integration of cost-effective technologies, business models and life cycle interaction for deep NZEB renovation to diverse residential renovation typologies and interconnecting both, building renovation stages and stakeholders. This innovation will establish a multi-collaborative framework within a refurbishment methodology managed by an Agile Project Management tool capable to interconnect in real-time the key steps of a tailored retrofitting plan among all stakeholders involved within the building renovation value chain. This ecosystem will ensure the fulfilment of three KPIs: 1)A deep renovation rate at least 60% of primary energy reduction as a result, the application of a decision tree strategy created from the combination of united principles of the novel sustainable architecture and NZEB design concepts; 2)A reduced installation time at least a 30% of time saving in comparison with a traditional refurbishment works,and; 3)A rapid payback period maximum 12 years of the best retrofitting technology package installed in the residential building. The environment will provide an ad-hoc amalgam of methodologies, cost-effective technologies and tools applicable within the main residential building typologies in EU, with the aim of achieving a large-scale penetration and deep impact within the rehabilitation of the current residential building stock after its optimization in 3 multi-scale demo buildings located in the most representative climates in EU.

The main goal of HIVACAR proposal is to change the current paradigm of HIV treatment by obtaining a functional cure for HIV (i.e., control of viral load to levels below the threshold of 50 copies/ml and maintenance of high CD4+ T-cell count after discontinuation of antiretroviral therapy) thanks to effectively targeting residual virus replication and viral reservoirs. In order to do so, the planned novel strategy is to successfully combine immune-based therapies, including therapeutic vaccines and broadly neutralizing antibodies with latency reversing agents, in a proof-of-concept phase IIa clinical trial. HIVACAR project will lead to a reduction of the actual costs related to HIV treatment and management and of the social public health as well as an improvement in the patients’ quality of life. HIVACAR project has been conceived under the framework of responsible research and innovation, so patients and other stakeholders will have a key role from the inception of the project until obtaining the results. Patients will be perfectly aware of how this therapy has been conceived and the real impact and change in their actual quality of life, as well as how the clinical trial has been designed and the consequences of participating in it. In addition, patients (and the general population) will tailor the project and its results dissemination and communication. This patient engagement will not be limited to the clinical trial but also to the rest of the activities of the project, so patients and the general society will be aware of how the research is developed and can include the patients’ point of view in the research activities. In addition, the socio-economic and psycho-social impact of the new treatment will be also analysed so overwhelming data on the benefits and impact of the new treatment will be obtained and shown to all the stakeholders.